Activated patients
2,369.6
patients
PSP Connect value estimator
From referral to sustained support: model enrollment leakage, continuity, team workload and reporting readiness in one linked program view.
Scenario assessment
CentralPersistent at 12 months
1,627.4
patients
Additional capacity required
40.1
hours
Enrollment & continuity funnel
BaselineModelled
Eligible referrals4,000 → 4,000
Consented / enrolled2,800 → 2,940
Activated patients2,100 → 2,369.6
Persistent at 12 months1,365 → 1,627.4
70%
Digital support reach
Of patients; limits where improvement assumptions apply
Stage conversion rates
BaselineModelled
Consented / enrolled70% → 73.5%
Activated patients75% → 80.6%
Persistent at 12 months65% → 68.7%
Administrative workloadhours
Baseline3,290
Hours before assumed efficiency3,872.2
Modelled3,330.1
All program metrics
| Enrollment & continuity funnel | Baseline | Modelled |
|---|---|---|
| Eligible referrals | 4,000 | 4,000 |
| Consented / enrolled | 2,800 | 2,940 |
| Activated patients | 2,100 | 2,369.6 |
| Persistent at 12 months | 1,365 | 1,627.4 |
| Completed planned contacts | 7,560 | 9,526 |
| Patients with refill gaps | 420 | 391 |
| Complete required-data records | 1,960 | 2,263.8 |
| Safety handoffs with recorded ownership | 80 | 87 |
| Admin hours required | 3,290 | 3,330.1 |
Patient counts are annual cohorts, not patient-years. Persistence is not adherence; refill rescues are not added again to retained patients.
Administrative workload
- Hours before assumed efficiency
- 3,872.2
- Hours avoided on supported work
- 542.1
- Net remaining capacity (hours)
- -40.1
- Supported refill-gap patients assisted
- 82.9
Planning scenarios
| Planning scenarios | Persistent at 12 months | Net remaining capacity (hours) |
|---|---|---|
| Conservative | 1,458.3 | 4.2 |
| Central | 1,627.4 | -40.1 |
| Stretch | 1,873 | -155.7 |
Ranges are illustrative assumptions, not study confidence intervals. Custom edits affect the selected scenario only.
No published benchmark is used as a universal enrollment, consent, safety or retention target. Select therapy-specific definitions and validate assumptions with your clinical, pharmacovigilance and finance teams.
Gaps to investigate—not assumed universal rates
Enrollment leakage
Eligibility, consent and activation are different steps. Review incomplete enrollment and time to first meaningful support.
Continuity & refill access
Track persistence at a defined horizon, reasons for discontinuation and actionable refill gaps; distinguish access barriers from clinician-directed changes.
Uncompleted follow-up
Monitor completed contacts against planned contacts, outreach reach and educator queue age.
Fragmented reporting & safety ownership
Review required-field completeness, handoff ownership and acknowledgement time. Ownership coverage does not establish safety-reporting compliance.
How the models compound
- 1.
Eligible → consented → activated → persistent. Each downstream stage uses the preceding cohort; supported reach limits every improvement assumption.
- 2.
Contact delivery and refill assistance use activated patients. Persistence, PDC and refill support remain distinct measures; their effects are not multiplied or added as clinical gains.
- 3.
Workload compares baseline enrollment/contact administration with the larger modelled cohort, adds refill-rescue work, then applies supported-work efficiency. Growth can require extra staff time.
- 4.
Budget impact values only net administrative capacity and deducts added enrollment, digital support, fixed operating and implementation costs. Payer study comparisons remain outside program economics.
References & model boundaries
No published benchmark is used as a universal enrollment, consent, safety or retention target. Select therapy-specific definitions and validate assumptions with your clinical, pharmacovigilance and finance teams.
Mean PDC 64.8% versus 50.1% (+14.7 percentage points); 29.2% lower medical costs, excluding biologic/targeted drugs.
Sponsor-funded US observational adalimumab study; 2,268 matched patients. All-cause medical costs exclude biologic/targeted drugs; total cost including those drugs was not significantly lower (p=0.056). Associations, not causal effects. PDC is not the proportion of adherent patients. Supplied PSP report, pp. 4 & 7.
12-month discontinuation 51.4% vs 65.9%; approximately 22% relative reduction. The optional continuity comparison applies (65.9 − 51.4) / 65.9 to your local discontinuation gap.
Source-derived assumption, not a forecast. Same observational cohort as PDC and medical-cost findings: correlated endpoints, not independent additive effects. No universal PSP target is inferred.
Israel, 1,520 adalimumab initiators: median time to discontinuation 673 vs 574 days for PSP vs non-PSP participants.
Sponsor-funded retrospective Clalit cohort. Different health system; median days cannot be converted into a universal 12-month persistence gain. Context for continuity KPIs, not an applied multiplier.
Canadian observational cohort of 10,857 patients assessed care-coach calls, treatment-initiation abandonment, persistence and adherence.
Sponsor-funded adalimumab-specific evidence. Supports measuring enrollment-to-initiation and contact completion; no unverified numeric effect is inserted into the model.
US commercial adalimumab study examined first-fill abandonment, distinct from later adherence or persistence.
Related sponsor/data source to the 2019 PDC study, with possible population overlap. Non-additive evidence for activation gaps—not an independent financial effect.